Trade BioCryst - BCRX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 7.97 |
| Open* | 8.05 |
| 1-Year Change* | -50.28% |
| Day's Range* | 7.93 - 8.05 |
| 52 wk Range | 7.61-18.00 |
| Average Volume (10 days) | 3.40M |
| Average Volume (3 months) | 61.80M |
| Market Cap | 1.53B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 188.45M |
| Revenue | 270.83M |
| EPS | -1.33 |
| Dividend (Yield %) | N/A |
| Beta | 2.04 |
| Next Earnings Date | May 3, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 20, 2023 | 7.97 | -0.10 | -1.24% | 8.07 | 8.10 | 7.91 |
| Mar 17, 2023 | 8.05 | 0.01 | 0.12% | 8.04 | 8.15 | 7.97 |
| Mar 16, 2023 | 8.14 | -0.07 | -0.85% | 8.21 | 8.40 | 8.13 |
| Mar 15, 2023 | 8.34 | 0.21 | 2.58% | 8.13 | 8.57 | 8.12 |
| Mar 14, 2023 | 8.29 | -0.14 | -1.66% | 8.43 | 8.57 | 8.22 |
| Mar 13, 2023 | 8.29 | 0.11 | 1.34% | 8.18 | 8.51 | 8.15 |
| Mar 10, 2023 | 8.26 | 0.11 | 1.35% | 8.15 | 8.27 | 7.79 |
| Mar 9, 2023 | 8.17 | -0.32 | -3.77% | 8.49 | 8.60 | 8.06 |
| Mar 8, 2023 | 8.52 | -0.08 | -0.93% | 8.60 | 8.65 | 8.36 |
| Mar 7, 2023 | 8.63 | -0.19 | -2.15% | 8.82 | 8.87 | 8.62 |
| Mar 6, 2023 | 8.81 | 0.07 | 0.80% | 8.74 | 8.81 | 8.64 |
| Mar 3, 2023 | 8.75 | -0.13 | -1.46% | 8.88 | 8.91 | 8.71 |
| Mar 2, 2023 | 8.81 | 0.15 | 1.73% | 8.66 | 8.87 | 8.59 |
| Mar 1, 2023 | 8.79 | -0.04 | -0.45% | 8.83 | 8.90 | 8.60 |
| Feb 28, 2023 | 8.81 | -0.17 | -1.89% | 8.98 | 9.10 | 8.74 |
| Feb 27, 2023 | 8.99 | -0.15 | -1.64% | 9.14 | 9.17 | 8.94 |
| Feb 24, 2023 | 9.07 | -0.20 | -2.16% | 9.27 | 9.30 | 9.02 |
| Feb 23, 2023 | 9.41 | -0.18 | -1.88% | 9.59 | 9.70 | 9.21 |
| Feb 22, 2023 | 9.72 | 0.59 | 6.46% | 9.13 | 9.81 | 8.78 |
| Feb 21, 2023 | 8.59 | -0.10 | -1.15% | 8.69 | 9.04 | 8.09 |
BioCryst Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total revenue | 157.17 | 17.812 | 48.835 | 20.653 | 25.186 |
| Revenue | 157.17 | 17.812 | 48.835 | 20.653 | 25.186 |
| Cost of Revenue, Total | 7.264 | 1.676 | 4.101 | 0.471 | 1.702 |
| Gross Profit | 149.906 | 16.136 | 44.734 | 20.182 | 23.484 |
| Total Operating Expense | 279.052 | 194.58 | 148.29 | 114.873 | 82.597 |
| Selling/General/Admin. Expenses, Total | 118.818 | 67.929 | 37.121 | 13.614 | 13.933 |
| Research & Development | 208.808 | 122.964 | 107.068 | 84.888 | 66.962 |
| Operating Income | -121.882 | -176.768 | -99.455 | -94.22 | -57.411 |
| Interest Income (Expense), Net Non-Operating | -59.927 | -6.046 | -9.442 | -7.032 | -8.371 |
| Net Income Before Taxes | -181.809 | -182.814 | -108.897 | -101.252 | -65.782 |
| Net Income After Taxes | -184.062 | -182.814 | -108.897 | -101.252 | -65.782 |
| Net Income Before Extra. Items | -184.062 | -182.814 | -108.897 | -101.252 | -65.782 |
| Net Income | -184.062 | -182.814 | -108.897 | -101.252 | -65.782 |
| Income Available to Common Excl. Extra. Items | -184.062 | -182.814 | -108.897 | -101.252 | -65.782 |
| Income Available to Common Incl. Extra. Items | -184.062 | -182.814 | -108.897 | -101.252 | -65.782 |
| Diluted Net Income | -184.062 | -182.814 | -108.897 | -101.252 | -65.782 |
| Diluted Weighted Average Shares | 179.117 | 167.267 | 115.6 | 103.185 | 84.451 |
| Diluted EPS Excluding Extraordinary Items | -1.02761 | -1.09295 | -0.94202 | -0.98127 | -0.77894 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -1.23024 | -1.08092 | -0.94202 | -0.82717 | -0.77894 |
| Total Extraordinary Items | 0 | ||||
| Unusual Expense (Income) | -55.838 | 2.011 | 15.9 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 49.923 | 47.158 | 40.994 | 49.959 | 19.059 |
| Revenue | 49.923 | 47.158 | 40.994 | 49.959 | 19.059 |
| Cost of Revenue, Total | 0.238 | 0.419 | 0.615 | 0.343 | 5.887 |
| Gross Profit | 49.685 | 46.739 | 40.379 | 49.616 | 13.172 |
| Total Operating Expense | 99.88 | 43.497 | 85.578 | 79.541 | 70.436 |
| Selling/General/Admin. Expenses, Total | 34.282 | 35.387 | 34.992 | 26.325 | 22.114 |
| Research & Development | 65.36 | 63.529 | 49.971 | 52.873 | 42.435 |
| Operating Income | -49.957 | 3.661 | -44.584 | -29.582 | -51.377 |
| Interest Income (Expense), Net Non-Operating | -23.96 | -19.187 | -14.217 | -13.616 | -12.907 |
| Net Income Before Taxes | -73.917 | -15.526 | -58.801 | -43.198 | -64.284 |
| Net Income After Taxes | -74.196 | -17.779 | -58.801 | -43.198 | -64.284 |
| Net Income Before Extra. Items | -74.196 | -17.779 | -58.801 | -43.198 | -64.284 |
| Net Income | -74.196 | -17.779 | -58.801 | -43.198 | -64.284 |
| Income Available to Common Excl. Extra. Items | -74.196 | -17.779 | -58.801 | -43.198 | -64.284 |
| Income Available to Common Incl. Extra. Items | -74.196 | -17.779 | -58.801 | -43.198 | -64.284 |
| Diluted Net Income | -74.196 | -17.779 | -58.801 | -43.198 | -64.284 |
| Diluted Weighted Average Shares | 184.898 | 181.871 | 179.106 | 178.127 | 177.343 |
| Diluted EPS Excluding Extraordinary Items | -0.40128 | -0.09776 | -0.3283 | -0.24251 | -0.36248 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.40128 | -0.29732 | -0.3283 | -0.24251 | -0.36248 |
| Unusual Expense (Income) | -55.838 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 566.136 | 323.8 | 164.345 | 114.352 | 125.391 |
| Cash and Short Term Investments | 507.601 | 300.366 | 136.226 | 104.467 | 114.397 |
| Cash & Equivalents | 504.389 | 272.127 | 114.172 | 26.731 | 50.282 |
| Short Term Investments | 3.212 | 28.239 | 22.054 | 77.736 | 64.115 |
| Total Receivables, Net | 29.413 | 8.646 | 22.146 | 4.293 | 6.117 |
| Accounts Receivable - Trade, Net | 29.413 | 8.646 | 22.146 | 4.293 | 6.117 |
| Total Inventory | 15.791 | 7.039 | 0 | 1.649 | |
| Prepaid Expenses | 9.986 | 5.528 | 4.422 | 2.39 | 1.381 |
| Other Current Assets, Total | 3.345 | 2.221 | 1.551 | 1.553 | 3.496 |
| Total Assets | 588.151 | 334.715 | 175.282 | 146.841 | 178.259 |
| Property/Plant/Equipment, Total - Net | 15.186 | 10.915 | 10.937 | 9.135 | 9.546 |
| Property/Plant/Equipment, Total - Gross | 25.925 | 20.892 | 18.911 | 15.23 | 14.873 |
| Accumulated Depreciation, Total | -10.739 | -9.977 | -7.974 | -6.095 | -5.327 |
| Long Term Investments | 6.829 | 0 | 22.376 | 41.295 | |
| Other Long Term Assets, Total | 0.978 | 2.027 | |||
| Total Current Liabilities | 103.718 | 105.654 | 92.335 | 69.477 | 74.836 |
| Accounts Payable | 27.808 | 18.713 | 13.988 | 7.769 | 6.337 |
| Accrued Expenses | 74.489 | 56.791 | 37.646 | 27.739 | 24.794 |
| Notes Payable/Short Term Debt | 0 | 30 | 29.561 | 29.121 | 28.682 |
| Other Current Liabilities, Total | 1.421 | 0.15 | 2.12 | 0.221 | 8.484 |
| Total Liabilities | 695.137 | 353.977 | 137.03 | 97.606 | 94.492 |
| Total Long Term Debt | 585.457 | 244.452 | 41.289 | 28.075 | 19.501 |
| Long Term Debt | 585.457 | 244.452 | 41.289 | 25.372 | 16.75 |
| Capital Lease Obligations | 2.703 | 2.751 | |||
| Other Liabilities, Total | 5.962 | 3.871 | 3.406 | 0.054 | 0.155 |
| Total Equity | -106.986 | -19.262 | 38.252 | 49.235 | 83.767 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 1.843 | 1.769 | 1.541 | 1.101 | 0.984 |
| Additional Paid-In Capital | 1098.5 | 1002.41 | 877.3 | 780.4 | 714.869 |
| Retained Earnings (Accumulated Deficit) | -1207.5 | -1023.44 | -840.628 | -731.969 | -631.843 |
| Other Equity, Total | 0.177 | 0.003 | 0.039 | -0.297 | -0.243 |
| Total Liabilities & Shareholders’ Equity | 588.151 | 334.715 | 175.282 | 146.841 | 178.259 |
| Total Common Shares Outstanding | 184.35 | 176.883 | 154.082 | 110.063 | 98.411 |
| Current Port. of LT Debt/Capital Leases | 0 | 9.02 | 4.627 | 6.539 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 511.714 | 566.136 | 252.743 | 265.802 | 273.771 |
| Cash and Short Term Investments | 443.468 | 507.601 | 199.597 | 218.428 | 240.356 |
| Cash & Equivalents | 395.504 | 504.389 | 199.597 | 210.314 | 226.902 |
| Short Term Investments | 47.964 | 3.212 | 0 | 8.114 | 13.454 |
| Total Receivables, Net | 36.415 | 29.413 | 26.212 | 27.62 | 18.386 |
| Accounts Receivable - Trade, Net | 36.415 | 29.413 | 26.212 | 27.62 | 18.386 |
| Total Inventory | 16.144 | 15.791 | 13.663 | 9.846 | 5.113 |
| Prepaid Expenses | 12.333 | 9.986 | 8.975 | 5.56 | 5.908 |
| Other Current Assets, Total | 3.354 | 3.345 | 4.296 | 4.348 | 4.008 |
| Total Assets | 527.72 | 588.151 | 265.763 | 277.284 | 284.431 |
| Property/Plant/Equipment, Total - Net | 16.006 | 15.186 | 13.02 | 11.482 | 10.66 |
| Property/Plant/Equipment, Total - Gross | 9.098 | 7.519 | 5.924 | 6.565 | |
| Accumulated Depreciation, Total | -3.019 | -2.626 | -2.328 | -2.111 | -2.94 |
| Total Current Liabilities | 81.017 | 103.718 | 133.608 | 115.601 | 101.201 |
| Accounts Payable | 13.881 | 27.808 | 19.693 | 10.087 | 13.529 |
| Accrued Expenses | 65.665 | 74.489 | 83.313 | 74.963 | 57.267 |
| Notes Payable/Short Term Debt | 0 | 0 | 30 | 30 | 30 |
| Other Current Liabilities, Total | 1.471 | 1.421 | 0.602 | 0.551 | 0.405 |
| Total Liabilities | 691.935 | 695.137 | 412.807 | 383.359 | 359.419 |
| Total Long Term Debt | 604.461 | 585.457 | 274.164 | 263.658 | 254.335 |
| Long Term Debt | 604.461 | 585.457 | 274.164 | 263.658 | 254.335 |
| Other Liabilities, Total | 6.457 | 5.962 | 5.035 | 4.1 | 3.883 |
| Total Equity | -164.215 | -106.986 | -147.044 | -106.075 | -74.988 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1.856 | 1.843 | 1.798 | 1.787 | 1.777 |
| Additional Paid-In Capital | 1115.44 | 1098.5 | 1040.77 | 1022.97 | 1010.78 |
| Retained Earnings (Accumulated Deficit) | -1281.7 | -1207.5 | -1189.72 | -1130.92 | -1087.73 |
| Other Equity, Total | 0.186 | 0.177 | 0.114 | 0.087 | 0.182 |
| Total Liabilities & Shareholders’ Equity | 527.72 | 588.151 | 265.763 | 277.284 | 284.431 |
| Total Common Shares Outstanding | 185.572 | 184.35 | 179.791 | 178.725 | 177.67 |
| Long Term Investments | 0 | 6.829 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -184.062 | -182.814 | -108.897 | -101.252 | -65.782 |
| Cash From Operating Activities | -142.157 | -135.108 | -89.584 | -92.565 | -41.143 |
| Cash From Operating Activities | 0.777 | 0.748 | 0.724 | 0.77 | 0.704 |
| Non-Cash Items | 33.004 | 20.083 | 19.461 | 11.447 | 14.608 |
| Changes in Working Capital | 8.124 | 26.875 | -0.872 | -3.53 | 9.327 |
| Cash From Investing Activities | 15.804 | -6.856 | 77.934 | 4.768 | -64.642 |
| Capital Expenditures | -2.385 | -0.514 | -0.343 | -0.366 | -0.328 |
| Other Investing Cash Flow Items, Total | 18.189 | -6.342 | 78.277 | 5.134 | -64.314 |
| Cash From Financing Activities | 359.668 | 300.589 | 99.098 | 62.504 | 135.703 |
| Issuance (Retirement) of Stock, Net | 65.794 | 110.542 | 79.621 | 56.252 | 135.581 |
| Issuance (Retirement) of Debt, Net | 293.874 | 190.047 | 19.477 | 6.252 | 0.122 |
| Net Change in Cash | 233.386 | 158.625 | 87.448 | -25.293 | 29.918 |
| Foreign Exchange Effects | 0.071 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -74.196 | -184.062 | -166.283 | -107.482 | -64.284 |
| Cash From Operating Activities | -77.8 | -142.157 | -109.698 | -86.422 | -61.011 |
| Cash From Operating Activities | 0.317 | 0.777 | 0.606 | 0.377 | 0.178 |
| Non-Cash Items | 28.634 | 33.004 | 62.615 | 35.809 | 16.52 |
| Changes in Working Capital | -32.555 | 8.124 | -6.636 | -15.126 | -13.425 |
| Cash From Investing Activities | -38.472 | 15.804 | 26.924 | 19.177 | 14.673 |
| Capital Expenditures | -0.406 | -2.385 | -1.277 | -0.912 | -0.099 |
| Other Investing Cash Flow Items, Total | -38.066 | 18.189 | 28.201 | 20.089 | 14.772 |
| Cash From Financing Activities | 7.356 | 359.668 | 12.25 | 7.474 | 2.9 |
| Issuance (Retirement) of Stock, Net | 7.356 | 65.794 | 12.25 | 7.474 | 2.9 |
| Net Change in Cash | -108.876 | 233.386 | -70.455 | -59.686 | -43.438 |
| Foreign Exchange Effects | 0.04 | 0.071 | 0.069 | 0.085 | |
| Issuance (Retirement) of Debt, Net | 293.874 | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.5177 | 14167131 | 359744 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.9264 | 13052882 | 1132849 | 2022-12-31 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 6.7449 | 12710818 | 0 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.9044 | 11126861 | 1722614 | 2022-12-31 | LOW |
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 4.8023 | 9050000 | 0 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 3.1084 | 5857788 | 1330751 | 2022-12-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 2.8046 | 5285348 | 471576 | 2022-12-31 | LOW |
| Fisher Investments | Investment Advisor/Hedge Fund | 2.3513 | 4431114 | -732731 | 2022-12-31 | LOW |
| RP Management, LLC | Private Equity | 2.0409 | 3846154 | 0 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8395 | 3466550 | 100706 | 2022-12-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 1.5274 | 2878427 | 228811 | 2022-12-31 | LOW |
| BNP Paribas Asset Management USA, Inc. | Investment Advisor | 1.4181 | 2672382 | 562718 | 2022-12-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3746 | 2590392 | -25765 | 2022-12-31 | HIGH |
| Fairmount Funds Management LLC | Hedge Fund | 1.3495 | 2543107 | 0 | 2022-12-31 | HIGH |
| Victory Capital Management Inc. | Investment Advisor/Hedge Fund | 1.3444 | 2533584 | -986647 | 2022-12-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.3185 | 2484819 | -562152 | 2022-12-31 | HIGH |
| PFM Health Sciences, LP | Hedge Fund | 1.1475 | 2162411 | 0 | 2022-12-31 | MED |
| Woodline Partners LP | Hedge Fund | 1.0989 | 2070983 | 2070983 | 2022-12-31 | HIGH |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.0878 | 2050026 | 2014048 | 2022-12-31 | LOW |
| Point72 Asset Management, L.P. | Hedge Fund | 1.0552 | 1988627 | 1988627 | 2022-12-31 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
BioCryst Company profile
BioCryst (BCRX) is a commercial-stage biotech firm that discovers novel, oral, small-molecule medicines.
The company focuses on oral treatments for rare diseases in which significant unmet medical needs exist. BioCryst’s drug portfolio consists of ORLADEYO for prevention of hereditary angioedema. ORLADEYO has been approved in the US, EU, UK, Japan and UAE. Other drugs like RAPIACTA, RAPIVAB and PERAMIFLU are approved in select geographies.
The company is developing an oral small molecule Factor D inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
According to the company, its focus on rare diseases market helps it control costs effectively. BioCryst selects disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market.
BioCryst’s US headquarters is located in Durham, North Carolina while its European headquarters is in Dublin, Ireland. Jon P Stonehouse is the chief executive officer and William P Sheridan is the chief medical officer of BioCryst.
The company was founded in 1966. It completed its initial public offering (IPO) in March 1994 and is listed on the Nasdaq stock exchange under the ticker symbol BCRX. According to the company’s price history, BCRX stock price hit an all-time high of $37.25 on 1 March 2000.
You can follow the ups and downs of the BioCryst stock price at Capital.com. Always stay on top of the latest price developments with our live BCRX stock chart.
| Industry: | Bio Therapeutic Drugs |
4505 Emperor Blvd Ste 200
DURHAM
NORTH CAROLINA 27703-8457
US
Income Statement
- Annual
- Quarterly
News
German bunds rate forecast: Two-year yields see highest drop in 30 years
Will Germany bonds continue to rise as the ECB raises rates?
15:05, 21 March 2023
Cryptogpt price prediction: What is cryptogpt (GPT)?
Can GPT cash in on the AI bubble?
16:43, 20 March 2023
Polygon price prediction: What is polygon (MATIC)?
Can MATIC outperform the market?
15:44, 20 March 2023
Ethereum price prediction 2030-2050: Will it fit your retirement plan?
What is the outlook for ETH as a long-term investment?
15:27, 20 March 2023
Ripple/SEC Lawsuit: News And Update
Ripple and the US Securities and Exchange Commission are still awaiting a ruling
15:14, 20 March 2023
UBS Group shareholders: Who owns the company that is acquiring troubled bank Credit Suisse?
Now that UBS is acquiring troubled bank Credit Suisse, who are the UBS Group shareholders?
14:20, 20 March 2023
DXY forecast: Will rate hikes support USD dominance?
Interest rate hikes helped the DXY surge to a 20-year high in 2022, but the index has since slid as the Fed has signalled a slowing of its monetary contraction policy. Where next for the DXY?
18:49, 17 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com